medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2024, Number 03

<< Back

Ginecol Obstet Mex 2024; 92 (03)

Description of the contributing factors to deaths secondary to hypertensive disorders associated with pregnancy in Antioquia, Colombia (2012-2020)

Vélez CSM, Rendón ZJ, Caicedo-Bolaños AM

Language: Spanish
References: 33
Page: 127-136
PDF size: 215.56 Kb.


ABSTRACT

Objective: To describe the characteristics of the affected population and the delays that contributed to maternal mortality secondary to hypertensive disorders of pregnancy.
Materials and Methods: Descriptive and retrospective study based on the epidemiologic surveillance of sentinel cases of early maternal deaths of women residing in Antioquia, Colombia, during pregnancy, delivery and the 42 days after delivery occurring in the period 2012-2020. A database was created in Microsoft Access 2007 (Microsoft, Redmond, WA, USA), and data were analyzed in Microsoft Excel and SPSS version 22.
Results: There were 266 maternal deaths, of which 38 were secondary to hypertensive disorders of pregnancy. Eclampsia was the cause of 15 deaths; 12 due to HELLP syndrome, 9 due to intracerebral hemorrhage, and 2 due to placental abruption and disseminated intravascular coagulation. In 13 of the 38 cases, there was no adequate magnesium sulfate regimen, 19 did not receive indicated antihypertensive treatment, and 17 did not have adequate antihypertensive control.
Conclusion: Antenatal care is a critical opportunity for detection, prevention, and risk stratification. All obstetric care centers should be prepared to manage emergencies associated with hypertensive disorders of pregnancy. Outcomes improve with the use of standardized, organized emergency protocols and the participation of multidisciplinary teams that ensure quality care and a positive impact on preventable maternal morbidity and mortality.


REFERENCES

  1. Say L, Chou D, Gemmill A, Tunçalp Ö, Moller AB, Daniels J,et al. Global causes of maternal death: A WHO systematicanalysis. Lancet Glob Heal 2014; 2 (6): 1-11. https://doi.org/10.1016/S2214-109X(14)70227-X

  2. Magee LA, Nicolaides KH, Von Dadelszen P. Preeclampsia. NEngl J Med 2022; 386 (19): 1817-32. https://www.binasss.sa.cr/mayo/37.pdf

  3. Hypertension G. Gestational hypertension and preeclampsia:ACOG Practice Bulletin, Number 222. ObstetGynecol 2020; 135 (6): e237-60. https://doi.org/10.1097/AOG.0000000000003891

  4. Márquez L, Plana A, Villarroel MC. Mortalidad materna enpueblos indígenas y fuentes de datos: alcances y desafíospara su medición en países de América Latina. 2017.https://hdl.handle.net/11362/42029

  5. Instituto Nacional de Salud INS. Dirección de Vigilanciay Análisis del Riesgo en Salud Pública. Boletín epidemiológicosemanal. Boletín 5, Semana epidemiológica 52 de2022. Publicación en línea: ISSN 2357-6189. https//doi.org/10.33610/23576189.2022.52

  6. Agalakova NI, Kolodkin NI, Adair CD, Trashkov AP, BagrovAY. Preeclampsia: Cardiotonic Steroids, Fibrosis, Fli1 andHint to Carcinogenesis. Int J Mol Sci 2021; 22 (4): 1941.https://doi.org/10.3390/ijms22041941

  7. Roos N, von Xylander SR. Why do maternal and newborndeaths continue to occur? Best Pract Res Clin ObstetGynaecol 2016; 36: 30-44. https://doi.org/10.1016/j.bpobgyn.2016.06.002

  8. Ma'ayeh M, Costantine MM. Prevention of preeclampsia.Semin Fetal Neonatal Med 2020; 25 (5): 101123. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237364/pdf/nihms-1717595.pdf

  9. Zuleta-Tobón JJ, Pandales-Pérez H, Sánchez S, Vélez-ÁlvarezGA, Velásquez-Penagos JA. Errors in the treatment ofhypertensive disorders of pregnancy and their impact onmaternal mortality. Int J Gynecol Obstet 2013; 121 (1): 78-81. https://doi.org/10.1016/j.ijgo.2012.10.031

  10. Thaddeus S, Maine D. Too To Walk : Maternal Mortalityin. Soc Sci Med 1994; 38 (8): 1091-110. https://doi.org/10.1016/0277-9536(94)90226-7

  11. Maine D, Akalin MZ, Ward VM, Kamara A. Diseño yevaluación de programas para mortalidad materna.Programa Nac Unidas para el Desarrollo 1997;1-72. https://www.researchgate.net/profile/Murat-Akalin-2/publication/265872457_Diseno_y_evaluacion_de_programas_para_mortalidad_materna/links/54b75eaf0cf2e68eb2800e72/Diseno-y-evaluacionde-programas-para-mortalidad-materna.pdf

  12. Scottish Programme for Clinical Effectiveness in ReproductiveHealth, Adamson L, Penney G. Scottish confidentialaudit of severe maternal morbidity: 4th annual report2006. Edinburgh: Scottish Programme for Clinical Effectivenessin Reproductive Health; 2007. https://www.ossyr.org.ar/pdf/bibliografia/2.8.pdf

  13. Departamento Administrativo Nacional de EstadísticaDANE. Nacimientos y defunciones. https://www.dane.gov.co/index.php/estadisticas-por-tema/demografia-ypoblacion/nacimientos-y-defunciones.

  14. Ghulmiyyah L, Sibai B. Maternal Mortality From Preeclampsia/Eclampsia. Semin Perinatol 2012; 36 (1): 56-9. https://doi.org/10.1053/j.semperi.2011.09.011

  15. Nyfløt LT, Ellingsen L, Yli BM, Øian P, Vangen S. Maternaldeaths from hypertensive disorders: lessons learnt. ActaObstet Gynecol Scand 2018; 97 (8): 976-87. https://doi.org/10.1111/aogs.13357

  16. Instituto Nacional de Salud. Boletín epidemiológico semanal52 de 2021. Boletín epidemiológico Sem 2021; 1-29.https://doi.org/10.33610/23576189.2021.52

  17. Lawrence ER, Klein TJ, Beyuo TK. Maternal Mortality inLow and Middle-Income Countries. Obstet Gynecol ClinNorth Am 2022; 49 (4): 713-733. https://doi.org/10.1016/j.ogc.2022.07.001

  18. Nyfløt LT, Ellingsen L, Yli BM, Øian P, Vangen S. Maternaldeaths from hypertensive disorders: lessons learnt. ActaObstet Gynecol Scand 2018; 97 (8): 976-87. https://doi.org/10.1111/aogs.13357

  19. Schutte J, Steegers E, Schuitemaker N, Santema J, de Boer K,Pel M, et al. Rise in maternal mortality in the Netherlands.BJOG An Int J Obstet Gynaecol 2010; 117 (4): 399-406.https://doi.org/10.1111/j.1471-0528.2009.02382.x

  20. Verona-Balcázar M, Fernández-Mogollón JL, Neciosup-PuicanE. Características epidemiológicas, clínicas y demorasen el proceso de atención en casos de muerte materna,Región Lambayeque, 2011-2016. Rev del Cuerpo Médicodel HNAAA 2019; 12 (2): 97-103. https://doi.org/10.35434/rcmhnaaa.2019.122.504

  21. Harris M, Henke C, Hearst M, Campbell K. Future Directions:Analyzing Health Disparities Related to MaternalHypertensive Disorders. J Pregnancy 2020; 2020: 1-5.https://doi.org/10.1155/2020/7864816

  22. Ronsmans C, Campbell O. Quantifying the fall in mortalityassociated with interventions related to hypertensivediseases of pregnancy. BMC Public Health 2011; 11 (Suppl3): S8.https://doi.org/10.1186/1471-2458-11-S3-S8

  23. Hauspurg A, Jeyabalan A. Postpartum preeclampsia oreclampsia: defining its place and management amongthe hypertensive disorders of pregnancy. Am J Obstet Gynecol2022; 226 (2S): S1211-S1221. https://doi.org/10.1016/j.ajog.2020.10.027

  24. Hauspurg A, Countouris ME, Catov JM. HypertensiveDisorders of Pregnancy and Future Maternal Health: HowCan the Evidence Guide Postpartum Management? CurrHypertens Rep 2019; 21 (12): 96. https://doi.org/10.1007/s11906-019-0999-7

  25. Poniedziałek-Czajkowska E, Mierzyński R, Leszczyńska-Gorzelak B. Preeclampsia and Obesity-The Preventive Roleof Exercise. Int J Environ Res Public Health 2023; 20 (2):1267. https://doi.org/10.3390/ijerph20021267

  26. Rolnik DL, Nicolaides KH, Poon LC. Prevention of preeclampsiawith aspirin. Am J Obstet Gynecol 2022; 226 (2S):S1108-S1119. https://doi.org/10.1016/j.ajog.2020.08.045

  27. Fishel Bartal M, Sibai BM. Eclampsia in the 21st century.Am J Obstet Gynecol 2022; 226 (2): S1237-53. https://doi.org/10.1016/j.ajog.2020.09.037

  28. Duley L, Henderson-Smart DJ, Chou D. Magnesiumsulphate versus phenytoin for eclampsia. CochraneDatabase Syst Rev 2010; (10): CD000128.. https://doi.org/10.1002/14651858.CD000128.pub2

  29. Henderson-Smart DJ, Walker GJ, Chou D. Magnesium sulphateversus diazepam for eclampsia. Cochrane Database Syst Rev2010. https://doi.org/10.1002/14651858.CD000127.pub2

  30. Belfort MA, Anthony J, Saade GR, Allen JC. A Comparisonof Magnesium Sulfate and Nimodipine for the Preventionof Eclampsia. N Engl J Med 2003; 348 (4): 304-11. https://doi.org/10.1056/NEJMoa021180

  31. Altman D, Carroli G, Duley L, Farrell B, Moodley J, NeilsonJ, et al. Do women with pre-eclampsia, and their babies,benefit from magnesium sulphate? The Magpie Trial:a randomised placebo-controlled trial. Lancet 2002;359 (9321): 1877-90. https://doi.org/10.1016/S0140-6736(02)08778-0

  32. Karolinski A, Mazzoni A, Belizán JM, Althabe F, Bergel E,Buekens P. Lost opportunities for effective management ofobstetric conditions to reduce maternal mortality and severematernal morbidity in Argentina and Uruguay. Int J GynaecolObstet 2010; 110 (2): 175-80. https://doi.org/10.1016/j.ijgo.2010.05.002

  33. Sinkey RG, Battarbee AN, Bello NA, Ives CW, Oparil S, TitaATN. Prevention, Diagnosis, and Management of HypertensiveDisorders of Pregnancy: a Comparison of InternationalGuidelines. Curr Hypertens Rep 2020; 22 (9): 66. https://doi.org/10.1007/s11906-020-01082-w




2020     |     www.medigraphic.com